Eighty serum samples from patients with bronchopulmonary aspergillosis {50 patients with aspergilloma, 19 with allergic bronchopulmonary aspergillosis (ABPA), 9 with
Aspergillus pneumonia, and each one with tracheal aspergillosis and bronchial stump aspergillosis}, and 88 sera for controls (several kinds of fungal diseases except aspergillosis, respiratory tract diseases, healthy adults, etc.) were studied for antibody response to
Aspergillus fumigatus antigens by means of counterimmunoelectrophoresis (CIE).
Two antigens, called J antigen and T antigen, were used for CIE. The former is our own crude antigen produced by a selected strain of
A. fumigatus (ATCC 26430), and the latter is a semicommercial one produced by Torii pharmaceutical compancy.
The patients with aspergilloma were classified into 8 groups by the certainty of diagnosis using their chest roentgenograms and fungal cultural examinations of their sputa, in conjunction with testing their sera.
The results were as follows: Out of 50 sera from patients with aspergilloma, 45 (90%) and 44 (88%) reacted positively to J antigen and T antigen, respectively, and out of 19 sera from patients with ABPA, 5 (26.3%) reacted positively to both antigens. The sera from the other aspergillosis and those from the controls reacted negatively to both antigens. No significant statistical difference in the positive reaction rates was noted among the 8 groups of the patients with aspergilloma.
In this study, no difference was detected in sensitivity, specificity, and efficacy between J antigen and T antigen in diagnosis of bronchopulmonary aspergillosis. The author thus hopes that the
A. fumigatus crude antigen used for serodiagnosis in his laboratory can be mass-produced and made available to all researchers.
CIE test was a satisfactory method for the diagnosis of aspergilloma because of its simplicity, rapidity, and specificity.
View full abstract